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Abstmef: Synthetic 1-motpholino-1-deoxyceramides wete designed to inhibit glucosylceramide synthase. The 
most potent inhibitor 2a possesses the unnatural RR-configuration of D-three-sphingosine. 
Eucaryotic glycosphingolipids (GSLs) affect membrane physical pmperties, cell-cell and cell-matrix 
interactions, adhesiveness, cellular immune responses, and differentiation.t GSLs have also been implicated in 
cancer cell metabolism.2 For example, malignant cells display marked abnormalities in their relative propottions of 
glycolipids.3 and produce GSLs with novel linkage and sugar specificities.4 Tumor cells also synthesize and shed 







GSL biosynthesis begins with the coupling of UDP-glucose to Cl of an N-acylsphingosine @amide). 
The reaction is catalyzed by glucosykemmide synthase (GlcCer synthase; ceramide:UDP-glucose glucosyltrans- 
ferase; EC 2.4.1.80). probably via a transition stmcture like 1.5 The enzyme plays a pivotal role in GSL biosyn- 
thesis and tepresents a promising cancer chemotherapy target, since inhibitors can retard or arrest tumor gmwth.~ 
Here we mport studies defining I-morpholinoldeoxyceramides such as 2a as potent GlcCer synthase inhibitors. 
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more potent, sphingosine-based GlcCer synthase inhibitors 
containing glucopyranose analogs having ring conformations 
related to 1. 8 To probe this stereochemical issue, we developed 
syntheses of all four isomeric 1-morpholino-l-deoxyceramides 
2a-d, as shown in the Scheme. 
Inhibit~ design was based on the observation that D-threo-1-phenyl-2-decanoylamino-3-morpholino-1- 
propanol (PDMP) 3 is an active competitive inhibitor of GlcCer synthase. 7 Presuming that the morpholine ring 
mimics the cationic charge of the GlcCer synthase Ixansition state 1, the syn-stereochemistry in 3 suggests that the 
bioactive (1R,2R)-PDMP stereoisomer is at variance with the D-erythro-or ant/-configuration of naturally- 
occurring GSLs shown in (2S,3R)-1. This stereochemical difference was a central concern in our plan to design 
OH 
O ~  I~IH-CO-R 
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Our synthetic approach was based on the method of Evans eta/. for the enantioselectlve aldol condensation 
of oxazofidinone 4 with unsaturated aldehyde 5. 9 According to Abdel-Magld etal., lO the observed stereochemis- 
try of condensation is influenced by chelation to the oxazofidinone oxygen in the transition state. In fact, 
condensation of 5 with the tin(II) enolate of 4 (prepared as shown in the Scheme) gave mostly 6c, whereas the 
Zn(II) enolate of 4 gave an inseparable mixture of 6a and 6b. Both reactions gave minor amounts of the (2S,3S) 
isomer 6d, which could be separated by flash column chromatography. 
The mixture of bromohydrins 6a and 6b could not be resolved, but was separable after conversion to the 
corresponding azides 7a and 7b, following the procedure of Nicolaon et a/.11 Alcohol 7a was then protected as 
its t-butyldimethylsilyl ether, and the chiral auxiliary was reductively removed to afford sphingol ether 8a. The 
primary alcohol in 8a was next activated as its u'iflate, and displacement with morpholine afforded aminoether 9a. 
Reduction of the azide group in 9a was effected by wansfer hydrogenation using ammonium formate as the 
hydrogen source. Subsequent N-acylation and desilylation led to the final product 2a in good overall yield. 12 
This consitutes the first use of metal-dependent aldol condensations in sphingosine synthesis, and the first 
synthesis of 1-azaceramides. Diastercomers 2b-d were synthesized in like fashion from aldol adducts 6b-d. 
Morpholinoceramides 2a-d were evaluated as inhibitors of GlcCer synthase from Madin-Darby canine 
kidney cell homogenates, using octanoyl sphingosine as glucose acceptor (thermostatted ulwasonic bath, wiplicate 
assays). 13 Diastereomer 2a was clearly the most powerful inhibitor of GlcCer synthase (73% inhibition at 51.tM), 
and was significantly more potent than PDMP 3 (16-20% inhibition at 5~tM) or isomers 2b-d (5-20% at 5~M). 
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These fWings set the stage for the refinement of GlcCer synthase transition structure mimics. including 
bi-substrate analogs and other active inhibitors based on the corresponding glucoamidrazone and glucoamidoxime 
derivatives8 of sphingosine. 
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